期刊论文详细信息
BMC Cancer
The radiosensitising effect of gemcitabine and its main metabolite dFdU under low oxygen conditions is in vitro not dependent on functional HIF-1 protein
An Wouters3  Bea Pauwels3  Natalie Burrows6  Marc Baay3  Vanessa Deschoolmeester3  Trung Nghia Vu2  Kris Laukens2  Paul Meijnders1  Dirk Van Gestel1  Kaye J Williams5  Danielle Van den Weyngaert1  Jan B Vermorken7  Patrick Pauwels4  Marc Peeters7  Filip Lardon3 
[1] Department of Radiotherapy, University Radiotherapy Antwerp (URA), Lindendreef 1, 2020 Antwerp, Belgium
[2] Biomedical Informatics Research Center Antwerp (Biomina), University of Antwerp, Middelheimlaan 1, 2020 Antwerpen, Belgium
[3] Center for Oncological Research Antwerp, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium
[4] Department of Pathology, Antwerp University Hospital, Wilrijkstraat 10, 2650 Edegem, Belgium
[5] Hypoxia and Therapeutics Group, University of Manchester, Oxford Road, Manchester M13 9PT, UK
[6] Cambridge Institute for Medical Research, University of Cambridge, 4.17 Wellcome Trust/MRC Building, Addenbrooke’s Hospital, Hills Road, Cambridge CB2 0XY, UK
[7] Department of Oncology, Antwerp University Hospital, Wilrijkstraat 10, 2650 Edegem, Belgium
关键词: HIF-1;    dFdU;    Gemcitabine;    Radiosensitisation;    Hypoxia;   
Others  :  1125198
DOI  :  10.1186/1471-2407-14-594
 received in 2014-04-08, accepted in 2014-08-05,  发布年份 2014
PDF
【 摘 要 】

Background

Regions within solid tumours often experience oxygen deprivation, which is associated with resistance to chemotherapy and irradiation. The aim of this study was to evaluate the radiosensitising effect of gemcitabine and its main metabolite dFdU under normoxia versus hypoxia and to determine whether hypoxia-inducible factor 1 (HIF-1) is involved in the radiosensitising mechanism.

Methods

Stable expression of dominant negative HIF-1α (dnHIF) in MDA-MB-231 breast cancer cells, that ablated endogenous HIF-1 transcriptional activity, was validated by western blot and functionality was assessed by HIF-1α activity assay. Cells were exposed to varying oxygen environments and treated with gemcitabine or dFdU for 24 h, followed by irradiation. Clonogenicity was then assessed. Using radiosensitising conditions, cells were collected for cell cycle analysis.

Results

HIF-1 activity was significantly inhibited in cells stably expressing dnHIF. A clear radiosensitising effect under normoxia and hypoxia was observed for both gemcitabine and dFdU. No significant difference in radiobiological parameters between HIF-1 proficient and HIF-1 deficient MDA-MB-231 cells was demonstrated.

Conclusions

For the first time, radiosensitisation by dFdU, the main metabolite of gemcitabine, was demonstrated under low oxygen conditions. No major role for functional HIF-1 protein in radiosensitisation by gemcitabine or dFdU could be shown.

【 授权许可】

   
2014 Wouters et al.; licensee BioMed Central Ltd.

【 预 览 】
附件列表
Files Size Format View
20150217011601163.pdf 1167KB PDF download
Figure 4. 49KB Image download
Figure 3. 62KB Image download
Figure 2. 23KB Image download
Figure 1. 41KB Image download
【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】
  • [1]Bertout JA, Patel SA, Simon MC: The impact of O2 availability on human cancer. Nat Rev Cancer 2008, 8:967-975.
  • [2]Wouters A, Pauwels B, Lardon F, Vermorken JB: Review: implications of in vitro research on the effect of radiotherapy and chemotherapy under hypoxic conditions. Oncologist 2007, 12:690-712.
  • [3]Moeller B, Dewhirst M: HIF-1 and tumour radiosensitivity. Br J Cancer 2006, 95:1-5.
  • [4]Pauwels B, Korst A, Lardon F, Vermorken J: Combined modality therapy of gemcitabine and radiation. Oncologist 2005, 10:34-51.
  • [5]Pauwels B, Vermorken JB, Wouters A, Ides J, Van LS, Lambrechts HA, Pattyn GG, Vermeulen K, Meijnders P, Lardon F: The role of apoptotic cell death in the radiosensitising effect of gemcitabine. Br J Cancer 2009, 101:628-636.
  • [6]Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN, Plunkett W: A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991, 9:491-498.
  • [7]Specenier P, Guetens G, Dyck J, de Boeck G, Weyler J, Van den Weyngaert D, Aelbrecht K, Vermorken JB: Difluorodeoxyuridine plasma concentrations after low-dose gemcitabine during chemoradiation in head and neck cancer patients. Cancer Chemother Pharmacol 2011, 68:185-191.
  • [8]Sasabe E, Zhou X, Li D, Oku N, Yamamoto T, Osaki T: The involvement of hypoxia-inducible factor-1alpha in the susceptibility to gamma-rays and chemotherapeutic drugs of oral squamous cell carcinoma cells. Int J Cancer 2007, 120:268-277.
  • [9]Hao J, Song X, Song B, Liu Y, Wei L, Wang X, Yu J: Effects of lentivirus-mediated HIF-1alpha knockdown on hypoxia-related cisplatin resistance and their dependence on p53 status in fibrosarcoma cells. Cancer Gene Ther 2008, 15:449-455.
  • [10]Rohwer N, Cramer T: Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat 2011, 14:191-201.
  • [11]Luwor RB, Lu Y, Li X, Mendelsohn J, Fan Z: The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. Oncogene 2005, 24:4433-4441.
  • [12]Wouters A, Pauwels B, Lambrechts HA, Pattyn GG, Ides J, Baay M, Meijnders P, Peeters M, Vermorken JB, Lardon F: Retention of the in vitro radiosensitizing potential of gemcitabine under anoxic conditions, in p53 wild-type and p53-deficient non-small-cell lung carcinoma cells. Int J Radiat Oncol Biol Phys 2011, 80:558-566.
  • [13]Huxham LA, Kyle AH, Baker JH, Nykilchuk LK, Minchinton AI: Microregional effects of gemcitabine in HCT-116 xenografts. Cancer Res 2004, 64:6537-6541.
  • [14]Ikeda R, Vermeulen LC, Jiang Z, Lau E, Kolesar JM: Gemcitabine and paclitaxel suppress the production of vascular endothelial growth factor induced by deferoxamine in human non-small cell lung cancer A549 cells. Exp Ther Med 2010, 1:853-857.
  • [15]Arora S, Bhardwaj A, Singh S, Srivastava SK, McClellan S, Nirodi CS, Piazza GA, Grizzle WE, Owen LB, Singh AP: An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factor kappaB- and hypoxia-inducible factor 1alpha-mediated up-regulation of CXCR4. J Biol Chem 2013, 288:21197-21207.
  • [16]Roberts DL, Williams KJ, Cowen RL, Barathova M, Eustace AJ, Brittain-Dissont S, Tilby MJ, Pearson DG, Ottley CJ, Stratford IJ, Dive C: Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells. Br J Cancer 2009, 101:1290-1297.
  • [17]Wouters A, Pauwels B, Lambrechts HA, Pattyn GG, Ides J, Baay M, Meijnders P, Dewilde S, Vermorken JB, Lardon F: Chemoradiation interactions under reduced oxygen conditions: Cellular characteristics of an in vitro model. Cancer Lett 2009, 286:180-188.
  • [18]Burrows N, Babur M, Resch J, Ridsdale S, Mejin M, Rowling EJ, Brabant G, Williams KJ: GDC-0941 inhibits metastatic characteristics of thyroid carcinomas by targeting both the phosphoinositide-3 kinase (PI3K) and hypoxia-inducible factor-1alpha (HIF-1alpha) pathways. J Clin Endocrinol Metab 2011, 96:E1934-E1943.
  • [19]Pauwels B, Korst AE, Lambrechts HA, Pattyn GG, De Pooter CM, Lardon F, Vermorken JB: The radiosensitising effect of difluorodeoxyuridine, a metabolite of gemcitabine, in vitro. Cancer Chemother Pharmacol 2006, 58:219-228.
  • [20]Wouters A, Pauwels B, Lambrechts HA, Pattyn GG, Ides J, Baay M, Meijnders P, Lardon F, Vermorken JB: Counting clonogenic assays from normoxic and anoxic irradiation experiments manually or by using densitometric software. Phys Med Biol 2010, 55:N167-N178.
  • [21]Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ, van der Wall E: Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 2003, 97:1573-1581.
  • [22]Dales JP, Garcia S, Meunier-Carpentier S, Andrac-Meyer L, Haddad O, Lavaut MN, Allasia C, Bonnier P, Charpin C: Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int J Cancer 2005, 116:734-739.
  • [23]Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, Jakesz R, Kubista E, Birner P, Oberhuber G, Austrian B, Colorectal Cancer Study G: Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 2002, 8:1831-1837.
  • [24]Liao D, Corle C, Seagroves TN, Johnson RS: Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res 2007, 67:563-572.
  • [25]Generali D, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield S, Bersiga A, Allevi G, Milani M, Aguggini S, Gandolfi V, Dogliotti L, Bottini A, Harris AL, Fox SB: Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res 2006, 12:4562-4568.
  • [26]Galban S, Kuwano Y, Pullmann R Jr, Martindale JL, Kim HH, Lal A, Abdelmohsen K, Yang X, Dang Y, Liu JO, Lewis SM, Holcik M, Gorospe M: RNA-binding proteins HuR and PTB promote the translation of hypoxia-inducible factor 1alpha. Mol Cell Biol 2008, 28:93-107.
  • [27]Wu Y, Jin M, Xu H, Shimin Z, He S, Wang L, Zhang Y: Clinicopathologic significance of HIF-1alpha, CXCR4, and VEGF expression in colon cancer. Clin Dev Immunol 2010., 2010doi:10.1155/2010/537531
  • [28]Beketic-Oreskovic L, Ozretic P, Rabbani ZN, Jackson IL, Sarcevic B, Levanat S, Maric P, Babic I, Vujaskovic Z: Prognostic significance of carbonic anhydrase IX (CA-IX), endoglin (CD105) and 8-hydroxy-2'-deoxyguanosine (8-OHdG) in breast cancer patients. Pathol Oncol Res 2011, 17:593-603.
  • [29]Pinheiro C, Sousa B, Albergaria A, Paredes J, Dufloth R, Vieira D, Schmitt F, Baltazar F: GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognostic factors and MCT1 overexpression. Histol Histopathol 2011, 26:1279-1286.
  • [30]Span PN, Bussink J, Manders P, Beex LV, Sweep CG: Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: association with treatment outcome. Br J Cancer 2003, 89:271-276.
  • [31]Betof AS, Rabbani ZN, Hardee ME, Kim SJ, Broadwater G, Bentley RC, Snyder SA, Vujaskovic Z, Oosterwijk E, Harris LN, Horton JK, Dewhirst MW, Blackwell KL: Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification. Br J Cancer 2012, 106:916-922.
  • [32]Favaro E, Lord S, Harris AL, Buffa FM: Gene expression and hypoxia in breast cancer. Genome Med 2011, 3:55.
  • [33]Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F, Blaydes JP, Brennan K, Brown NJ, Bryant HE, Bundred NJ, Burchell JM, Campbell AM, Carroll JS, Clarke RB, Coles CE, Cook GJ, Cox A, Curtin NJ, Dekker LV, Silva Idos S, Duffy SW, Easton DF, Eccles DM, Edwards DR, Edwards J, Evans D, Fenlon DF, Flanagan JM, Foster C, et al.: Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res 2013, 15:R92.
  • [34]Lam W, Bussom S, Cheng YC: Effect of hypoxia on the expression of phosphoglycerate kinase and antitumor activity of troxacitabine and gemcitabine in non-small cell lung carcinoma. Mol Cancer Ther 2009, 8:415-423.
  • [35]Onozuka H, Tsuchihara K, Esumi H: Hypoglycemic/hypoxic condition in vitro mimicking the tumor microenvironment markedly reduced the efficacy of anticancer drugs. Cancer Sci 2011, 102:975-982.
  • [36]Fechner G, Dederichs F, Schmidt D, Muller S, Vaupel P, Albers P: Hyperoxia-induced improvement of the in vitro response to gemcitabine in transitional cell carcinoma. Anticancer Res 2005, 25:3413-3418.
  • [37]Yokoi K, Fidler IJ: Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. Clin Cancer Res 2004, 10:2299-2306.
  • [38]Zhang X, Galardi E, Duquette M, Lawler J, Parangi S: Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model. Clin Cancer Res 2005, 11:5622-5630.
  • [39]Maftouh M, Avan A, Sciarrillo R, Granchi C, Leon LG, Rani R, Funel N, Smid K, Honeywell R, Boggi U, Minutolo F, Peters GJ, Giovannetti E: Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia. Br J Cancer 2014, 110:172-182.
  • [40]Yang L, Kang WK: The effect of HIF-1alpha siRNA on growth and chemosensitivity of MIA-paca cell line. Yonsei Med J 2008, 49:295-300.
  • [41]Cheng ZX, Wang DW, Liu T, Liu WX, Xia WB, Xu J, Zhang YH, Qu YK, Guo LQ, Ding L, Hou J, Zhong ZH: Effects of the HIF-1alpha and NF-kappaB loop on epithelialmesenchymal transition and chemoresistance induced by hypoxia in pancreatic cancer cells. Oncol Rep 2014, 31:1891-1898.
  • [42]Kasuya K, Tsuchida A, Nagakawa Y, Suzuki M, Abe Y, Itoi T, Serizawa H, Nagao T, Shimazu M, Aoki T: Hypoxia-inducible factor-1alpha expression and gemcitabine chemotherapy for pancreatic cancer. Oncol Rep 2011, 26:1399-1406.
  • [43]Staab A, Fleischer M, Loeffler J, Said HM, Katzer A, Plathow C, Einsele H, Flentje M, Vordermark D: Small interfering RNA targeting HIF-1alpha reduces hypoxia-dependent transcription and radiosensitizes hypoxic HT 1080 human fibrosarcoma cells in vitro. Strahlenther Onkol 2011, 187:252-259.
  • [44]Arvold ND, Guha N, Wang D, Matli M, Deen D, Warren R, Haas Kogan D: Hypoxia-induced radioresistance is independent of hypoxia-inducible factor-1A in vitro. Int J Radiat Oncol Biol Phys 2005, 62:207-212.
  • [45]Lagadec C, Dekmezian C, Bauche L, Pajonk F: Oxygen levels do not determine radiation survival of breast cancer stem cells. PLoS One 2012, 7:e34545.
  文献评价指标  
  下载次数:86次 浏览次数:15次